{
    "key_points": [
        "The FDA issued an emergency use authorization for Pfizer's Paxlovid, the first oral antiviral for COVID-19 treatment.",
        "Paxlovid is for adults and pediatric patients (12 years and older) who are at high risk of progressing to severe COVID-19.",
        "The drug should be prescribed and taken within five days of COVID-19 symptom onset.",
        "Paxlovid is not approved for pre-exposure or post-exposure prevention, nor for those already requiring hospitalization.",
        "Vaccination is still recommended as the primary defense against COVID-19.",
        "Paxlovid works by inhibiting a SARS-CoV-2 protein, preventing virus replication, with ritonavir prolonging its effect.",
        "The drug's authorization was based on a clinical trial showing it reduced hospitalization or death by 88% when taken early.",
        "Possible side effects include impaired taste, diarrhea, high blood pressure, and muscle aches.",
        "It's contraindicated with certain drugs due to potential serious interactions.",
        "Fact sheets for healthcare providers and patients/caregivers are required under the EUA."
    ],
    "spokespersons": [
        "Patrizia Cavazzoni, M.D. (director of the FDA\u2019s Center for Drug Evaluation and Research)"
    ],
    "article_type": "press release",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}